People On The Move: Appointments At Aboca, SkinBioTherapeutics, Reckitt
A round-up of the latest European health & wellness people moves: Aboca hires Germany head; SkinBioTherapeutics gets interim CEO; Reckitt adds experience to board.
HBW Insight - March 10, 2026

Actelion Settles Tracleer Antitrust Case For $65m Ahead Of Trial
A proposed settlement would resolve claims that Actelion used REMS restrictions to block generic rivals from accessing Tracleer samples, allegedly delaying competition and inflating prices for insurers and other payors.
Generics Bulletin - March 10, 2026

‘The Future Is Bright For Physician Adoption And Patient Access’ – Cardinal On US Biosimilar Trends
As the US biosimilars market continues to evolve, Cardinal Health’s director of biosimilars Dracey Poore talks to Generics Bulletin for an exclusive Q&A.
Generics Bulletin - March 10, 2026

Vitestro Raises $70M In Series B To Expand Autonomous Blood-Draw Robot In Europe, Eyes US Approval
Vitestro raised an oversubscribed $70M Series B to scale its autonomous blood-drawing system across the Netherlands and expand into Europe. The CE-marked robot has been tested in more than 10,000 patients, and the company is pursuing FDA clearance to enter the US market.
Medtech Insight - March 10, 2026

Vertex Ratchets Up Competition In IgAN With Povetacicept Phase III Win
Povetacicept’s Phase III results strengthen Vertex’s push to expand beyond cystic fibrosis, with the company expected to complete the drug’s rolling submission by the end of March.
Scrip - March 10, 2026

Medtronic Bolsters Neurovascular Portfolio With $550M Scientia Buy
This acquisition is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and accretive thereafter.
Medtech Insight - March 10, 2026

AbbVie Posts Encouraging Early-Stage Data For Amylin Analog ABBV-295
Phase I data for the long-acting amylin analog, which analysts touted as encouraging, highlights AbbVie's potential diversification beyond immunology and inflammation.
Scrip - March 10, 2026

Our Work Here Is Done: BioNTech Founders Moving On To Next Start-Up
Co-founders Ugur Sahin and Özlem Türeci will depart BioNTech to work on a new mRNA spin-out company, but the announcement has left investors uncertain about the German firm’s future
Scrip - March 10, 2026

Stock Watch: Tensions In Tough Times For Bayer
Geopolitical events overshadowed Bayer’s financial results announcement, as was also the case for its peers. But Bayer’s history of acquisition and slow portfolio rejuvenation compound the clouds over its investment proposition.
Scrip - March 10, 2026

Shilpa Biologicals To Enter Latin America With SteinCares Biosimilars Pact
Deal pairs SteinCares’ regional commercialization platform with Shilpa Biologicals’ development and manufacturing capabilities for an undisclosed biosimilar.
Generics Bulletin - March 10, 2026

Sandoz Splits Out Biosimilars And Generics With New Business Structure
Sandoz has unveiled a major reorganization of its generics and biosimilars operations into two distinct businesses, bringing in Ferring and Merck veteran Armin Metzger to lead a new global biosimilars unit while at the same time assigning existing executives to generics roles.
Generics Bulletin - March 10, 2026

‘The Pirates All Know Where The Treasure Is’ – Staying Ahead Of The Competition In US Biosimilars
At the AAM’s Access! 2026 conference, a dedicated panel on the latest developments for biosimilars discussed challenges and opportunities in the US market, predicting consolidation among current players as well as calling for policies that put biosimilars first.
In Vivo - March 10, 2026

Chairmen Of House Committees With FDA Oversight In Opposite Corners On Lawful Hemp
Delaying or altogether eliminating limits on all THCs in lawful hemp Congress approved in 2025 could come down to either House Appropriations AG/FDA subcommittee, chaired by a proponent for lower limits, or Energy and Commerce Health subcommittee, chaired by a supporter for eliminating lower limits.
HBW Insight - March 10, 2026